Quick adme quote
Innovative Mechanistic Toxicology Solutions
for Agrochemicals, Pharmaceuticals and Industrial Chemicals
Why are mechanistic toxicology solutions vital?
In an era of heightened regulatory scrutiny and environmental awareness, toxicology is critical for assessing the impact of chemicals in industrial, environmental, agrochemical, and consumer sectors. GLP compliant mechanistic toxicology studies supporting endocrine disruptor assessment, mode of action (MoA) interpretation, and regulatory decision making under REACH, CLP, ECHA, EFSA and FDA/EMA frameworks guide safer product development.
The expert team at Concept Life Sciences offer GLP-compliant mechanistic toxicology studies that support regulatory decision-making for agrochemical, industrial, and specialty chemical sectors to:
- Determine which toxicology pillars suit your needs
- Design staged testing strategies
- Understand species relevance for risk assessment
- Integrate toxicology with ADME/PK and biological endpoints
Our integrated in vitro, in vivo, and ex vivo platforms generate defensible mode-of-action data aligned with OECD guidelines and evolving regulatory expectations.
Regulatory leadership and method development
Helping you navigate:
- Regulatory uncertainty around endocrine and thyroid disruption
- Conflicting or inconclusive mechanistic data
- Evolving expectations under REACH, CLP, EFSA, and ECHA
Our focus is clear: delivering mechanistic clarity that supports credible regulatory submissions, protects product value, and enables your informed decision making.
Shaping the future of endocrine toxicology
Beyond study execution, our scientists actively contribute to industry led and collaborative initiatives that strengthen the mechanistic basis of endocrine disruptor assessment to support the evolution of OECD Test Guidelines.
- Thyroid molecular initiating events Development of DIO and TPO assays progressing toward OECD Test Guideline status, supporting early mechanistic insight.
- Cell proliferation and endocrine mechanisms Active participation in consortia working toward OECD Test Guideline development for cell proliferation assays.
- Regulatory ready science Assays designed for reproducibility, regulatory relevance, and future acceptance, protecting long-term value of your data.
Why this matters now?
Increasing regulatory scrutiny of endocrine and thyroid disruption requires robust mechanistic evidence to support hazard identification, adversity, and biological plausibility. Early, targeted mechanistic studies can reduce uncertainty and prevent unnecessary downstream testing.
We combine deep mechanistic expertise, advanced technologies, and regulatory insight to deliver tailored toxicology solutions that stand up to scrutiny, for industrial and agrochemical products.
Regulatory uncertainty and evolving expectations
Integrated and mechanistic approach
As a specialist CRO (contract research organisation) combining decades of regulatory toxicology expertise with modern mechanistic and New Approach Methodologies (NAMs)., we help regulatory, and safety teams navigate complex toxicological questions with confidence.
Our GLP-accredited laboratory enables you to have confidence in our integrated in vitro, in vivo, and ex vivo mechanistic toxicology platforms to generate defensible, regulator-ready MoA data packages aligned with OECD Test Guidelines and evolving regulatory expectations.
Whether you are addressing endocrine disruption, thyroid effects, or hepatic mode of action, our science is designed to directly answer the questions regulators ask, supporting hazard identification, risk assessment and classification decisions while minimising uncertainty and late-stage setbacks, to keep your products compliant, credible, and competitive.
What our clients say
“Concept Life Sciences delivered exactly what we needed, GLP-compliant mechanistic data with clear regulatory interpretation. Their responsiveness and expertise set them apart.”
Regulatory Toxicology Consultant
“CLS is the laboratory we refer to for bespoke mechanistic toxicology studies in carcinogenicity and endocrine disruption. Their scientific staff understood our regulatory needs and delivered high quality, fit for purpose results.”
Toxicology Client
Our clients range from regulatory, safety, and toxicology teams in:
- Agrochemical organisations
- Industrial and specialty chemical companies
- Biocidal and cosmetic product developers
- Environmental and sustainability research
They rely on us for mechanistic evidence that strengthens endocrine disruptor assessments, supports risk-based decision-making, and underpins regulatory confidence.
A trusted partner
- Regulatory Confidence GLP compliant, OECD aligned data suitable for REACH submissions, CLP classification, EFSA pesticide risk assessment, and ECHA endocrine disruptor evaluations.
- Risk Mitigation and Smarter Decisions Early mechanistic clarification of endocrine, thyroid, or hepatic signals helping avoid unnecessary testing or classification.
- Scientific Confidence Robust MoA evidence supporting weight of evidence (WoE) arguments and defensible regulatory narratives.
- Future Ready Strategies Alignment with NAMs, emerging OECD guidance, and future regulatory expectations.
Our Core Toxicology Pillars
Service
Purpose
Key Capabilities
Benefit
Mechanistic evidence for ECHA and EFSA endocrine disruptor identification.
• GLP-compliant in vitro assays covering the full EATS modalities.
• Estrogen, Androgen Receptor, Steroidogenesis, (OECD 455, 456, 458).
• Aromatase inhibition.
• Expanded thyroid Molecular Initiating Events (MIE) endpoints (TPO, DIO, NIS, TTR, UGT).
• Multi-species relevance assessment.
Clear mechanistic evidence to support endocrine disruptor identification, reduce ambiguity, and strengthen WoE arguments.
Interpretation of liver and thyroid findings and species relevance.
• Rat, mouse, dog, and human hepatocytes.
• CYP, UGT, and SULT induction (gene expression and enzyme activity).
• LC‑MS/MS metabolic profiling.
Defensible conclusions on human relevance or non-relevance of hepatic effects.
Integrated systemic and tissue-level insight.
• Targeted animal studies.
• Histopathology and hepatocyte proliferation.
• Gene expression and Hepatic enzyme activity (CYP, UGT).
• Thyroid hormones (T3, T4, TSH).
• IHC and IF.
Targeted in vivo and ex vivo studies (liver and thyroid focused endpoints) to support mechanistic interpretation, weight-of-evidence approaches, and regulatory decision-making.
NAMs and emerging technologies
Future-ready regulatory strategies aligned with the 3Rs.
• Custom NAM development.
• Fit-for-purpose solutions for emerging regulatory expectations.
Data packages aligned with future OECD and regulatory science expectations.
What makes us your go-to partner
- Specialist CRO focused on agrochemical, industrial chemical, Pharmaceutical and cosmetic sectors
- Full EATS panel with expanded thyroid molecular initiating events
- Integrated LC‑MS/MS
- Metabolic profiling
- Strong consultant network and deep regulatory insight
Need mechanistic clarity for a regulatory decision?
Speak directly with our scientists to discuss your regulatory challenge and identify the most appropriate mechanistic toxicology strategy.
Mechanistic toxicology FAQs
Q: What types of products and sectors do your mechanistic toxicology services support?
A: Our services are designed for agrochemicals, pharmaceuticals, industrial and specialty chemicals, biocides, cosmetics, and consumer products. We support regulatory, safety, and toxicology teams requiring mechanistic evidence to inform hazard identification, risk assessment, classification, and regulatory submissions under frameworks such as REACH, CLP, EFSA, and ECHA.
Q: How do your mechanistic studies support regulatory decision making?
A: We generate GLP-compliant, OECD-aligned MoA data that directly address regulatory questions around adversity, biological plausibility, and species relevance. Our studies strengthen weight-of-evidence (WoE) arguments, reduce uncertainty, and support defensible conclusions for endocrine disruption, thyroid effects, hepatic findings, and carcinogenicity-related mechanisms.
Q: Are your assays suitable for endocrine and thyroid disruptor assessments?
A: Yes. We offer a comprehensive EATS panel, including OECD Test Guidelines 455, 456, and 458, alongside expanded thyroid molecular initiating events such as TPO, DIO, NIS, TTR, and UGT. These assays are designed to provide early mechanistic clarity and are aligned with current and emerging regulatory expectations for endocrine disruptor identification.
Q: Do you provide GLP-compliant and regulator-ready data packages?
A: All relevant studies are conducted in our GLP-accredited laboratory and designed to meet OECD Test Guidelines and evolving regulatory standards. Our outputs are structured to be submission-ready, with clear scientific interpretation to support REACH dossiers, EFSA pesticide assessments, CLP classification, and ECHA endocrine disruptor evaluations.
Download and resource links:
No items found.